LONDON, Sept. 26 /PRNewswire-FirstCall/ -- Waters Corporation announced today it will expand its research collaboration with Imperial College London by equipping the Waters Laboratory of Molecular Spectroscopy at Imperial College London with three high-end research instruments -- the Waters(R) ACQUITY UPLC(TM) System, and Waters Q-Tof Premier(TM) and GCT Premier(TM) Mass Spectrometers.
The announcement was made as Imperial unveiled a new state-of-the-art NMR facility incorporating the mass spectrometry-based Waters Laboratory of Molecular Spectroscopy. This newly-equipped laboratory will allow the Division of Molecular Biosciences to leverage a unique alignment of instrumental resources -- mass spectrometry, high-resolution separations technologies, and nuclear magnetic resonance technology -- to drive broad research programs in the increasingly important area of systems biology.
Art Caputo, President of the Waters Division, attended the official ceremony hosted by Imperial College inaugurating the laboratory. Also attending from the Waters Division were: Dr. Rohit Khanna, Vice President of Worldwide Marketing; Brian Smith, Senior Director of Pharmaceutical Market Development; and Dr. Robert Plumb, Manager of Pharmaceutical Applications and Development.
The collaboration and new facility will allow researchers at Waters and Imperial to address fundamental medicinal-biology problems, which in turn will pave the way for a better understanding of the underlying causes of disease and the effect of lifestyle and diet on health and overall well-being. It is hoped that the work done at this laboratory will provide the tools necessary to make significant steps toward the goal of personalized medicine.
Thanking Waters Corporation for their support, Jeremy Nicholson head of Imperial’s Department of Biomolecular Medicine said, “I’m delighted to welcome Arthur Caputo and his colleagues from Waters Corporation. Their investment in the new mass spectrometry laboratory -- together with our new NMR facility -- means that the College has a uniquely powerful new facility for molecular structure elucidation, which will enable researchers here in the future to develop new disease diagnostics based on small molecule biomarkers and to understand molecular mechanisms of disease.”
“For the last four years Waters has enjoyed a strong relationship with Imperial College London,” said Art Caputo, President of the Waters Division. “During that time, we have worked on honing our expertise in the area of chemometric data analysis for metabonomics and biomedical applications and worked on strategies for creating more useful liquid chromatography and mass spectrometry tools for systems biology and structural characterization of biomolecules. We are delighted to be able to assist in continuing the important biological research with them and look forward to building on this relationship in the future.”
Also attending the inauguration ceremony were Imperial College London’s Rector, Sir Richard Sykes, Dr. Andres Ramos of the National Institute for Medical Research, Prof. David Barford of the Institute of Cancer Research, representatives of University College London, along with College faculty and staff members.
About Imperial College London
Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excellence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality.
Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment -- underpinned by a dynamic enterprise culture.
Website: http://www.imperial.ac.uk.
About Waters Corporation (http://www.waters.com)
Waters Corporation holds worldwide leading positions in three complementary analytical technologies -- liquid chromatography, mass spectrometry and thermal analysis. These markets account for approximately $5.0 billion of the overall $20 - $25 billion analytical instrument market.
Waters, ACQUITY UPLC, Q-Tof, Q-Tof Premier, and GCT Premier are trademarks of Waters Corporation.
Certain statements contained herein are forward looking. Many factors could cause actual results to differ from these statements, including delays in product introductions, loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company’s products, and foreign exchange fluctuations. Such factors are discussed in detail in the Company’s filings with the Securities and Exchange Commission and, in particular, the Company’s Annual Report on Form 10-K for the year ended December 31, 2005.
Media Contact (Imperial College): Media Contact (Waters): Danielle Reeves Brian J. Murphy Press Office Corporate Communications +44 (0)20 7594 2198 +1 508-482-2614 danielle.reeves@imperial.ac.ukbrian_j_murphy@waters.com Investor Contact (Waters): Gene Cassis V.P. - Investor Relations Waters Corporation +1-508-482-2349 gene_cassis@waters.com
Waters Corporation
CONTACT: Media Contact: Danielle Reeves, Press Office of Imperial College,+44 (0)20 7594 2198, danielle.reeves@imperial.ac.uk; or Investor Contact:Gene Cassis, V.P. - Investor Relations, +1-508-482-2349,gene_cassis@waters.com, or Media Contact: Brian J. Murphy, CorporateCommunications, +1 508-482-2614, brian_j_murphy@waters.com, both of WatersCorporation
